---
title: "688247.SH (688247.SH) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/688247.SH/news.md"
symbol: "688247.SH"
name: "688247.SH"
parent: "https://longbridge.com/zh-HK/quote/688247.SH.md"
datetime: "2026-03-13T15:01:32.567Z"
locales:
  - [en](https://longbridge.com/en/quote/688247.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688247.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688247.SH/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/688247.SH/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/688247.SH/news.md)


# 688247.SH (688247.SH) — 相關新聞

### [SINOTHERAPEUTICS: The cooperative product Enzalutamide tablets have been approved by the National Medical Products Administration](https://longbridge.com/zh-HK/news/279027988.md)
*2026-03-13T10:36:32.000Z*
> SINOTHERAPEUTICS announced that its collaboratively developed Enzalutamide tablets have obtained the drug registration c

### [Equipping Nutritional Products with "Formulation Core," SINOTHERAPEUTICS Expands into New Health Consumption Sector](https://longbridge.com/zh-HK/news/278718983.md)
*2026-03-11T12:08:51.000Z*
> The Chinese healthcare industry is undergoing profound changes. From the acceleration of innovative drug research and de

### [SINOTHERAPEUTICS Vitamin K1 tablets approved by the US FDA, adding new momentum to performance decline](https://longbridge.com/zh-HK/news/277750669.md)
*2026-03-04T08:57:37.000Z*
> SINOTHERAPEUTICS announced on March 2nd that its Vitamin K1 tablets have been approved by the U.S. FDA, qualifying them 

### [SINOTHERAPEUTICS: Vitamin K1 tablets have received approval from the U.S. FDA](https://longbridge.com/zh-HK/news/277426672.md)
*2026-03-02T08:11:07.000Z*
> SINOTHERAPEUTICS announced that its abbreviated new drug application (ANDA) for Vitamin K1 tablets has been approved by 

### [In 2025, SINOTHERAPEUTICS' net profit attributable to the parent company was 48.9463 million yuan, a year-on-year decrease of 61.67%](https://longbridge.com/zh-HK/news/277169377.md)
*2026-02-27T09:03:40.000Z*
> SINOTHERAPEUTICS released its performance preliminary report for the year 2025, reporting total operating revenue of 446

### [SINOTHERAPEUTICS: Ursodeoxycholic Acid Capsules are expected to be selected for the national drug continuation procurement](https://longbridge.com/zh-HK/news/275419242.md)
*2026-02-10T07:40:05.000Z*
> SINOTHERAPEUTICS announced that its product Ursodeoxycholic Acid Capsules is expected to be selected for the national dr